Kornimate/medical-research-clean huggingface dataset:
penn state txt2stayquit study- a texting study to help hospitalized smokers stay quit

Conditions: Nicotine Dependence, Cigarettes

Summary: this study aims to pilot a method of collecting the post-discharge follow-up data required by the joint commission tobacco measure set, using text messages sent to and received from patients' cellular-telephones. it also aims to assess whether specially designed relapse prevention text messages designed to encourage abstinence from smoking, can increase the proportion of smokers who remain abstinent during the first month after discharge from hospital.

participants will be those who are hospitalized at hershey medical center and are interested in help to stay quit when they leave the hospital.

Eligibility criteria:
inclusion criteria: * total length of hospital stay at least 24 hours * free of cognitive impairment * read and speak english * smoked at least 20 cigarettes in 30 days prior to entering the hospital * willing to give up all forms of tobacco * has a cell phone capable of receiving text messages (cell phone is powered on and charged) exclusion criteria: * patient has been admitted for a transplant * patient has intensive care status
symbicort single inhaler therapy for asthma in a general practice setting

Conditions: Asthma

Summary: the primary objective is to compare the effects of symbicort sit and treatment according to nhg-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by pd20 histamine, and to validate the bronchial hyperresponsiveness questionnaire (bhq).


Eligibility criteria:
inclusion criteria: * diagnosis of mild to moderate asthma, fev1 ³ 60% of predicted normal values pre-bronchodilator, daily use of inhaled gcs during the last 3 months exclusion criteria: * regular need of \>4 inhalations of a short-acting b2-agonist/day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any b-blocking agent, having smoked ³10 pack-years
the feasibility of chatbot-based stress management intervention stars for youth in lithuania

Conditions: Symptoms of Depression and Anxiety

Summary: the study aims to assess the feasibility of a chatbot-based stress management intervention among youth in lithuania.

the intervention is a chatbot-based stress management intervention developed by the world health organization (who). it consists of 10 sessions which include: introduction (1), psychoeducation (2), emotion regulation (3, 4), behavior activation (5, 6), managing problems (7), thought challenging (8, 9), and relapse prevention (10). each session consists of psychoeducation and exercise parts. trained e-helpers contact participants to support them individually on a weekly basis. the effect of the intervention will be compared against a control group which gets basic psychoeducation. the intervention is provided in lithuanian.

Eligibility criteria:
inclusion criteria: * age of 18-25 years * understanding the lithuanian language * having access to a device for intervention delivery * experiencing moderate levels of psychological distress exclusion criteria: * people at imminent risk of suicide * people currently experiencing a psychotic episode * people currently experiencing interpersonal violence * current dependency on alcohol/drugs

Keywords: intervention chatbot stress management youth stars feasibility
characteristics of persons with an eating disorder and type 1 diabetes

Conditions: Eating Disorder; Type 1 Diabetes

Summary: the purpose of this study is to analyze a chart audit of patients seen at park nicollet eating disorder institute (edi) to identify and compare general characteristics of eating disorders with type 1 diabetes patients to a matched eating disordered population without type 1 diabetes, also seen at edi.

the goal of this study is to conduct a chart audit on all patients with type 1 diabetes who have been seen collaboratively by international diabetes center (idc) and park nicollet eating disorder institute (edi) staff from 2005 - 2008 and their matched eating disordered controls. research questions 1. what are the general characteristics of the ed dm t1 population? 2. how are ed dm t1 patients different from the matched eating disordered patients with respect to race, marital status, age of onset, eating behaviors, self-reported highest and lowest weight, exercise frequency and duration, number of hospital admissions, number of emergency room visits, medication needs, and other medical and psychological/psychiatric comorbidities? 3. how are ed dm t1 patients different from the matched eating disordered patients with respect to the affective and cognitive aspects of eating disorders such as self-reported depression symptoms, body image distortion, thoughts and feelings about eating, psychological concerns, readiness to change, self-esteem and anxiety? 4. for ed dm t1 patients, what is the time relationship of the diagnosis of diabetes and an eating disorder? 5. for ed dm t1 patients, what is the relationship of bmi and a1c?

Eligibility criteria:
inclusion criteria: * patient seen in both park nicollet eating disorder institute and international diabetes center for type 1 diabetes from 2005 - 2008 * patient seen only in park nicollet eating disorder institute from 2005 - 2008 exclusion criteria: * none

Keywords: dual diagnosis
combining transcranial direct current stimulation with intermittent oral to esophageal tube for stroke-related dysphagia

Conditions: Stroke

Summary: the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

transcranial direct current stimulation is currently very popular. the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for ischemic stroke confirmed by mri or ct; * age \> 18 years; * first-time stroke; * swallowing disorder confirmed by swallowing contrast study or flexible endoscopic evaluation of swallowing; * requires enteral nutrition support; * stable vital signs, no severe cognitive impairment or aphasia, able to cooperate with treatment; * transferred to the rehabilitation department within fifteen days of onset; * stable vital signs. exclusion criteria: * presence of contraindications for invasive oral endoscopy; * concurrent presence of other neurodegenerative diseases that may cause swallowing disorders, such as neurodegenerative diseases; * concurrent presence of other neurological disorders; * tracheostomized patients; * concurrent liver, kidney failure, tumor, or hematological disorders; * pregnancy; * presence of contraindications for transcranial direct current stimulation, such as epilepsy, cerebral edema; * recent use of centrally acting drugs that interfere with the effects of transcranial direct current stimulation, such as carbamazepine, phenytoin, valproic acid, etc.
pharmacokinetics, safety and tolerability of oral semaglutide in subjects with hepatic impairment

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe. the aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (nnc0113-0217) in subjects with mild, moderate and severe degrees of hepatic impairment compared to subjects with normal hepatic function.


Eligibility criteria:
inclusion criteria: * subject with normal hepatic function or hepatic impairment (mild, moderate or severe) * body mass index (bmi) 18.5-40.0 kg/m\^2 (both inclusive) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods * history of crohn's disease, ulcerative colitis, or other inflammatory bowel disease * uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmhg and/or diastolic blood pressure above or equal to 100 mmhg) * any donation of blood or plasma in excess of 400 ml within the 3 months preceding screening * history of significant drug abuse, or a positive drug test at the screening visit (visit 2)
exercise and quality diet after leukemia: the equal study

Conditions: Adult Survivors of Childhood Leukemia

Summary: the equal study has been designed for adult survivors of childhood acute lymphoblastic leukemia (all) who are overweight or obese. the purpose of this study is to see if diet and exercise can help people lose weight and improve other health problems. this two year study will compare two methods of informing participants about ways to lose weight.


Eligibility criteria:
inclusion criteria: eligibility will be confirmed via the ccss-based medical record and by a series of questions on the equal website, prior to consent. * participation in the ccss cohort * diagnosed with acute lymphoblastic leukemia \< 18 years of age * cancer free at time of study enrollment * current age ≥ 18 years * a body mass index (bmi) ≥ 25 kg/m2 (overweight or obese), as determined by self-reported height and weight on the most recent ccss questionnaire * internet access and a personal email account * able to read and comprehend informed consent exclusion criteria: * prior history of congestive heart failure, coronary artery disease, myocardial infarction, stroke, or unstable angina; * medical condition for which weight loss might be contraindicated or which would cause weight loss, such as pregnancy, anorexia or bulimia; * use of prescription weight loss medication within the previous 6 months * history of total body irradiation (tbi)

Keywords: equal exercise diet physical activity 14-164
benchmarking intra-tumor heterogeneity in ovarian cancer: linking in-vivo imaging phenotypes with histology and genomics

Conditions: Ovarian Cancer

Summary: the purpose of this research study is to learn if differences seen in scans before surgery match differences seen when looking at tumor samples with pathology and genetic tests. in this study we will use magnetic resonance imaging \[mri\] and positron emission tomography \[pet\] scans. no direct clinical benefits will come from the results of this study.


Eligibility criteria:
inclusion criteria: * ≥18 years of age on the day of signing the informed consent. * histologically confirmed or suspected stage iii or iv high-grade serous ovarian cancer. * scheduled to undergo primary debulking surgery. exclusion criteria: * pregnant patients * patients who because of general medical or psychiatric condition, or physiologic status unrelated to the presence of ovarian cancer cannot give valid informed consent * patients who are unwilling or unable to undergo mri including patients with contraindications to mri such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc. * patients with a metallic hip implant or any other metallic implant or device in the pelvis that might distort local magnetic field and compromise quality of mri/ * radiotherapy to the abdomen or pelvis within 6 months of the screening visit. subjects with a current diagnosis of epithelial ovarian tumor of low malignant potential (borderline carcinomas) are not eligible * patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met: * stage not greater than ib * no more than superficial myometrial invasion * no vascular or lymphatic invasion * no poorly differentiated subtypes, including serous, clear cell, or other figo grade 3 lesions. * patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded. patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded. patients may have received prior adjuvant chemotherapy for breast cancer. * with the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with other invasive malignancies who had (or have) any evidence of the other cancer present within the last 3 years are excluded. * unresolved bowel obstruction. * history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study. * absence of target lesions (\> 2.0 cm) on staging ct * patients unlikely to be optimally debulked at surgery (tumor implants in difficult to reach places \[i.e. falciform ligament or porta hepatis\], suprarenal retroperitoneal lymphadenopathy)

Keywords: mri fdg pet/ct histologic heterogeneity 14-061
impact of sunflower seed oil massage on neonatal mortality and morbidity in nepal

Conditions: Neonatal Mortality; Neonatal Sepsis

Summary: each year four million babies die during the neonatal period, with the majority occurring in developing countries. overall, infections account for one-third of all neonatal deaths, with proportions approaching 50% in settings where neonatal mortality rates are high. infections are predominately due to sepsis, respiratory infections, tetanus, and diarrhea. the investigators long term goal is to identify simple, affordable, and effective interventions that can be delivered at the community level in low-resource settings to reduce neonatal mortality risk due to these infections. the investigators team has conducted research in this area for the past 10 years, with specific focus on newborn vitamin a dosing and topical chlorhexidine antisepsis interventions. previous community-based research by the investigators group of investigators and others demonstrated that newborn vitamin a dosing can reduce early infant mortality by approximately 20%, and that topical applications of chlorhexidine to the umbilical cord can prevent omphalitis and reduce neonatal mortality risk by 24%. evidence is growing that neonatal skin plays an important role in protecting the newborn infant from invasive pathogens. barrier function of the neonatal skin, however, is incomplete in newborn infants, especially those that are pre-term or of low birth weight. full-body massage of newborns with mustard oil, practiced almost universally (\~95%) in communities of south asia, may further compromise skin barrier function through decreased structural integrity leading to increased trans-epidermal water loss and increased risk of percutaneous penetration by invasive pathogens. loss of structural integrity is not seen after massage of neonatal skin with alternative topical emollients, including sunflower seed oil. furthermore, sunflower seed oil has been shown to accelerate recovery of the skin barrier function, improve skin condition, and reduce the risk of both nosocomial infections and neonatal mortality among hospitalized newborns in low-resource settings. the specific hypothesis of this study is that substituting mustard oil with sunflower seed oil for topical applications during full body massage of newborns in the community will reduce neonatal mortality and morbidity by improving overall skin barrier function and reducing exposure to invasive pathogens.


Eligibility criteria:
inclusion criteria: * baby born alive * baby born in study area
pulmonary involvement in patients with fabry disease

Conditions: Fabry Disease

Summary: the objective of this study is to investigate whether agalsidase alpha, a drug commonly prescribed in patients with fabry disease, is associated with improvement of the pulmonary involvement. according to the global initiative for obstructive lung disease (gold), the surrogate markers for obstructive lung diseases are a decrease in both forced expiratory volume in one second (fev1) and fev1/fvc ratio, whereas fvc is the forced vital capacity. however, the measurement of these lung function parameters is indicated as yearly follow-up examinations with or without the treatment of agalsidase alpha in patients with fabry disease.

pulmonary function tests und dlco measurements are performed yearly in relation with yearly follow up examinations in the department of internal medicine from the university hospital of zurich. we will retrospectively collect the results of the pulmonary functions test (spirometry).

Eligibility criteria:
inclusion criteria: * all patients with established diagnosis of fabry disease exclusion criteria: * missing informed consent
a comprehensive study of clinically staged pediatric hodgkin's disease: chemotherapy for all patients; supplementary low dose involved field irradiation for selected patients (ccg 5942)

Conditions: Pediatric; Hodgkin's Disease

Summary: study hypothesis: clinical staging without laparotomy/splenectomy is adequate for children and young adults with hodgkin's disease who receive chemotherapy as a component of treatment.


Eligibility criteria:
* age less than 21 years at diagnosis * previously untreated, pathologically confirmed diagnosis of hodgkin's disease. * informed patient/parental consent as required by individual institution and in accordance with the dept of health and human services * approval of this protocol by the individual institutional human subjects review committee. * indicate hodgkin's disease clinical stage. * indicate presence or absence of "b" symptoms. * for stage i and ii disease indicate the following: * presence or absence of bulk disease * number of involved nodal regions * presence or absence of hilar adenopathy

Keywords: pediatric hodgkin's disease 96-016
accuracy of maxillary repositioning during orthognathic surgery

Conditions: Orthognathic Surgery; Maxillofacial Abnormalities

Summary: orthognathic surgery aims to correct jaw position taking into account esthetic and functional criteria (dental occlusion, lip position, breathing...). these surgeries are planned using clinical, radiological and dental cast data. the result of this planning are occlusal splints. orthognathic surgery had improved in the last decade with 3 dimensions computerized tomography scan (3d ct-scan) planning and osteosynthesis implants. however the accuracy of the operative results compared to the planned ones has rarely been measured.

orthognathic surgery aims to correct jaw position taking into account esthetic and functional criteria (dental occlusion, lip position, breathing...). these surgeries are planned only after the end of the growing period and in association with orthodontics. it is necessary to wait the end of facial growth to expect a stable result especially concerning mandibular. the age limit seems to be around 15 to 16 years old for retromandibular deformities and around 18 years old for premandibular deformities. these surgeries are planned using clinical, radiological and dental cast data. occlusal splints are made using all these results; these occlusal splints are used during the orthognathic surgery to maintain bones in the planned position. since 1993, a navigation system (orthopilot™) is used, which allow to track jaw position, in real time, with an accuracy around one millimeter and one degree, during orthognathic surgery. this system is routinely used for condyle repositioning after mandibular sagittal split osteotomies; but it is also useful for maxillary navigation and positioning. the investigator propose to measure the accuracy of the operative results compared to the planned ones, using the orthopilot™ system.

Eligibility criteria:
inclusion criteria: * patients needing orthognathic surgery with mobilization of the maxilla via a le fort i osteotomy, alone or associated to a mandibular osteotomy, whatever the indication (poor occlusion, sleep apnea, temporo-mandibular dysfunction...) * patient over 16 years old * having not expressed any opposition to the collection of his/her personal data for this study (patient him/herself or holder of parental authority in case of patients younger than 18) exclusion criteria: * pregnancy * patients deprived of liberty * protected adult * patients needing maxillary disjunction
panda: pku amino acid evaluation

Conditions: Phenylketonuria (PKU)

Summary: phenylketonuria (pku) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (pah), which leaves them unable to convert phenylalanine (phe) into tyrosine (tyr). pku patients have specific dietary needs and must follow a restrictive diet in the aim of preventing toxic levels of the amino acid phenylalanine (phe) accumulation.

the exploratory study's main objective is to measure blood amino acid levels and to gain quantitative insights in children with pku on a protein substitute with respect to evaluation of nutritional intake.

Eligibility criteria:
inclusion criteria: both pku and non-pku comparison subjects: 1. age ≥ 2 and ≤ 12 years 2. willing and able to provide informed consent by parents or legal representatives (and assent if required by local law/regulations) 3. one subject per family pku subjects specific inclusion criteria: 4. pku subjects identified by newborn screening and started low phe diet before 1 month age 5. usage of at least two phe-free protein substitutes on a daily basis for at least 26 consecutive weeks up to visit 1 6. average phe-level ≤360 µmol/l based on at least two blood phe values from the past 12 months up to visit 1 non-pku comparison subjects specific inclusion criteria: 7. same age (±3 years) and sex as an included pku subject exclusion criteria: both pku and non-pku comparison subjects: 1. current psychiatric disorders 2. severe hepatic, thyroid or renal dysfunction 3. acute illnesses like fever, flu, diarrhea, or vomiting (subjects should be symptom free for a week prior to v1) 4. serious conditions (e.g. cancer, hydrocephalus, fatal heart disease) 5. participation in any other clinical intervention studies involving test products concomitantly or within six weeks prior to entry into the study pku specific exclusion criteria: 6. use of bh4, or drugs that may interfere with main outcomes non-pku comparison subjects specific exclusion criteria: 7. pku diagnosis or any other diagnosed disorder of amino or organic acid metabolism